The protein corona protects against size- and dose-dependent toxicity of amorphous silica nanoparticles

• Dominic Docter,
• Christoph Bantz,
• Dana Westmeier,
• Hajo J. Galla,
• Qiangbin Wang,
• James C. Kirkpatrick,
• Peter Nielsen,
• Michael Maskos and
• Roland H. Stauber

Beilstein J. Nanotechnol. 2014, 5, 1380–1392, doi:10.3762/bjnano.5.151

• interface in general. Keywords: biobarrier; gastrointestinal tract; high-throughput profiling; nanomedicine; nanotoxicity; Introduction Besides the wide use of nanomaterials in industrial products, biomedical applications of nanoparticles (NP) are steadily increasing [1][2][3][4][5]. However, despite

• biomedical application as contrast agents or drug delivery devices [9][10]. From our experience in pharmaceutical and medical history, we have learned that oral delivery is the preferred administration route for patients [9][10]. Similar to the lung, also the GI tract is a major biobarrier target organ for

• MTT assay (Figure 6). Similar to the lung surfactant [32], also epithelial cell of the GI tract are covered by an additional biobarrier, i.e., by mucous matrices [33]. To investigate the impact of mucus associated to GI tract cells on the observed effects, we included the mucus-secreting colorectal